Merck Buys Silence Therapeutics for 1.3 Billion
Germany's Merck KGaA announced it will acquire Silence Therapeutics in an all-cash transaction valued at approximately 1.3 billion dollars. The acquisition strengthens Merck's gene-silencing capabilities by adding advanced RNA-targeting drug technology to its expanding pipeline.
Xurve View
Insights:
Xurve View
Merck KGaA will acquire Silence Therapeutics PLC in an all-cash deal worth $1.3B, adding RNA-targeting drug technology to its pipeline. The transaction represents a 130% premium to Silence shares before the announcement. The deal expands the German drugmaker's portfolio into gene-silencing therapies for rare blood cancers and cardiovascular conditions.
